Ultragenyx Pharmaceutical RARE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $669.71M+13.5% | $672.71M+20.1% | $630.08M+20.6% | $609.64M+26.7% | $590.17M+33.4% | ||
| $771.23M+12.5% | $750.23M+7.5% | $734.85M+9.6% | $688.75M+4.8% | $685.51M+3.7% | ||
| $349.2M+5.9% | $348.2M+8.5% | $342.15M+8.2% | $335.88M+8.1% | $329.84M+5.9% | ||
| -$561.06M-9.2% | -$535.06M+0.2% | -$544.08M-1.6% | -$505.18M+7.9% | -$513.65M+11.5% | ||
| -83.8%+3.3pp | -79.5%+16.2pp | -86.4%+16.1pp | -82.9%+31.2pp | -87%+44.1pp | ||
| $24.17M-31.3% | $25.17M-32.0% | $28.7M-19.9% | $33.57M+8.4% | $35.18M+19.1% | ||
| -$605.23M-10.7% | -$571.23M-0.7% | -$576.36M-2.6% | -$530.04M+9.8% | -$546.77M+11.2% | ||
| $3.69M+45.0% | $3.69M+84.5% | $3.2M+242% | $2.63M+238% | $2.55M+225% | ||
| -$608.92M-10.9% | -$574.92M-1.0% | -$579.57M-3.6% | -$532.67M+9.0% | -$549.32M+10.5% | ||
| -90.9%+2.2pp | -85.5%+16.1pp | -92%+15.1pp | -87.4%+34.3pp | -93.1%+45.7pp | ||
| -$6.10-3.9% | -$5.83+7.9% | -$5.93+7.2% | -$5.52+23.5% | -$5.87+26.2% | ||
| -$6.10-3.9% | -$5.83+7.9% | -$5.93+7.2% | -$5.52+23.5% | -$5.87+26.2% | ||
| 397.4M+7.7% | 393.1M+10.2% | 385M+13.3% | 380.8M+20.5% | 368.9M+22.8% | ||
| 397.4M+7.7% | 393.1M+10.2% | 385M+13.3% | 380.8M+20.5% | 368.9M+22.8% | ||
| $110.34M+24.7% | $109.34M+42.0% | $97.16M+35.6% | $90.19M+46.3% | $88.47M+76.0% | ||
| $1.23B+11.5% | $1.21B+10.2% | $1.17B+11.0% | $1.11B+8.3% | $1.1B+7.9% | ||
| $68.66M+12.3% | $61.66M-2.1% | $57.67M-11.1% | $59.23M-11.3% | $61.15M-7.6% | ||
| $669.71M+13.5% | $672.71M+20.1% | $630.08M+20.6% | $609.64M+26.7% | $590.17M+33.4% | ||
| -$561.06M-9.2% | -$535.06M+0.2% | -$544.08M-1.6% | -$505.18M+7.9% | -$513.65M+11.5% | ||
| -$527.06M-10.4% | -$500.06M0.0% | -$508.33M-1.5% | -$469.28M+9.0% | -$477.5M+13.3% | ||
| -$527.06M-10.4% | -$500.06M0.0% | -$508.33M-1.5% | -$469.28M+9.0% | -$477.5M+13.3% | ||
| -78.7%+2.2pp | -74.3%+15.0pp | -80.7%+15.2pp | -77%+30.2pp | -80.9%+43.6pp | ||
| -$561.06M-9.2% | -$535.06M+0.2% | -$544.08M-1.6% | -$505.18M+7.9% | -$513.65M+11.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ultragenyx Pharmaceutical's profit margins?
- Gross margin is 97.2% and operating margin is -83.8%, with a -90.9% net margin.
- Where does Ultragenyx Pharmaceutical's income statement data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.